Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: A multicenter retrospective study

Luca Moscetti, Fabrizio Nelli, Maria A. Fabbri, Isabella Sperduti, Daniele Alesini, Enrico Cortesi, Donatello Gemma, Teresa Gamucci, Roberta Grande, Ida Pavese, Daniela Franco, Enzo M. Ruggeri

Research output: Contribution to journalArticlepeer-review

Abstract

Summary: The addition of bevacizumab to standard chemotherapy has improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in both first- and second line treatment, but the role of maintenance bevacizumab remains controversial. The association of various clinical factor and survival was examined in this retrospective cohort analysis. The clinical data from 220 previously untreated patients with mCRC, not progressive at the end of standard chemotherapy plus bevacizumab, were collected and analyzed. Patients were classified into two subgroups: those given with maintenance bevacizumab: "maintenance bevacizumab cohort (n = 118; MB)", and those discontinuing bevacizumab as a result of physician's or patient's decision: "no maintenance bevacizumab cohort (n = 102; noMB)". The baseline factors were well balanced between the study subgroups. Median PFS and OS for the general population was 10 months (range 7-15) and 22.5 months (range 18-26), respectively. Median PFS was 13 and 8 months in the BM and noBM cohorts, respectively (p <0.0001). In the multivariate analysis, maintenance therapy resulted independently associated with improved PFS (HR 1.73; p <0.001), but only objective response (OR) after first-line chemotherapy was associated with improved OS. Maintenance chemotherapy cannot be considered a standard of care after induction chemotherapy for mCRC, because the optimal balance between efficacy and safety of maintenance therapy remains a significant challenge. The results of our retrospective study suggest that maintenance therapy with bevacizumab is a safe and valuable option, particularly in those patients achieving an objective response after first-line chemotherapy.

Original languageEnglish
Pages (from-to)1035-1043
Number of pages9
JournalInvestigational New Drugs
Volume31
Issue number4
DOIs
Publication statusPublished - Aug 2013

Keywords

  • Antiangiogenic therapy
  • Bevacizumab
  • Chemotherapy
  • Maintenance therapy
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: A multicenter retrospective study'. Together they form a unique fingerprint.

Cite this